Cynosure, the Cutera-owned aesthetic device subsidiary, has launched XERF, a next-generation monopolar RF platform, in European markets. The platform targets the growing demand for non-invasive skin tightening, positioning itself as a clinical and commercial alternative to existing monopolar RF systems like InMode's Morpheus8 and Lumenis' Thermage.
Devices & Tech
Cynosure Launches XERF Monopolar RF Platform in Europe — Next-Gen Skin Tightening Enters Market
Cutera's subsidiary rolls out next-generation monopolar RF technology targeting non-invasive skin tightening demand across the continent.
1-YEAR MOVE
INMD
▲1.0%
| Ticker | Company | 1-year change |
|---|---|---|
| INMD | InMode Ltd. | +1.0% |
Free alerts
Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
Next-generation monopolar RF enters Europe as skin-tightening demand accelerates.
Monopolar RF remains a high-margin procedure category for medspa owners—typically $2,000–$4,000 per treatment with minimal consumables. XERF's European entry signals Cynosure's intent to recapture market share in a segment where InMode has gained ground over the past three years. Practices currently using competing platforms should evaluate XERF's treatment parameters, handpiece ergonomics, and rebate/financing terms. The regulatory pathway in Europe is typically faster than FDA 510(k) review in the US, so North American availability may follow within 12–18 months.
Source: original report ↗
Frequently asked questions
What is the price range for monopolar RF skin tightening treatments?
Monopolar RF treatments typically cost $2,000–$4,000 per session, making it a high-margin procedure category for medspa owners with minimal consumable costs. Pricing can vary based on treatment area size and provider location.
How does Cynosure's XERF compare to Morpheus8 and Thermage?
XERF is Cynosure's next-generation monopolar RF platform designed as a clinical and commercial alternative to InMode's Morpheus8 and Lumenis' Thermage. Medspa owners should evaluate XERF's treatment parameters, handpiece ergonomics, and financing terms to determine which platform best fits their practice.
When will XERF be available in the United States?
XERF has launched in European markets first, where regulatory approval is typically faster than FDA 510(k) review. North American availability is expected within 12–18 months following the European rollout.
Why is InMode gaining market share in monopolar RF?
InMode has captured ground in the monopolar RF segment over the past three years, prompting Cynosure's XERF launch as a strategic effort to recapture market share in this high-margin procedure category.
What should medspa owners consider when switching to a new RF platform?
When evaluating a new monopolar RF system like XERF, assess treatment parameters, handpiece ergonomics for operator comfort, and rebate or financing terms offered by the manufacturer. These factors directly impact clinical outcomes, staff satisfaction, and practice profitability.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/moJoin the owners who run ahead of the industry. Cancel anytime, one click.